Cambridge, United States
Alltrna, founded in 2018 at Flagship Labs, is pioneering the use of transfer RNA (tRNA) to unlock vast therapeutic potentials in the field of biotechnology and health care. As the world’s first tRNA platform company, its mission is to advance tRNA therapeutics that can regulate the protein universe and address diseases driven by genetic mutations.
Utilizing its proprietary machine learning tools, Alltrna has meticulously mapped tRNA biology to design medicines that target disruptions in protein production, focusing on disease treatment and management. This innovative approach presents a groundbreaking opportunity to address both rare and common diseases associated with shared genetic underpinnings.
In August 2023, Alltrna secured a $109.00M Series B investment led by Flagship Pioneering, emphasizing investor confidence in the company’s potential to revolutionize therapeutic strategies from its base in the United States.
